Post-hoc analysis suggested attenuated benefit in the PD-L1 1–49% group (HR 0.87, 95% CI 0.60–1.26) and minimal benefit in patients with tumour PD-L1 < 1% (HR 0.97, 95% CI 0.72–1.31). The gene discussed is CD274; the disease is neoplasm.